All In Biotech

NDA 018701 · Janssen Pharms

Haldol

Haloperidol Decanoate · Injection

Discontinued

Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Jan 14, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

170

51 Phase 3, 4 recruiting

FAERS reports

1,743

1,546 serious, 153 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with...

What it is approved for

From the label in effect Feb 19, 2025.

INDICATIONS AND USAGE Haloperidol decanoate 50 and Haloperidol decanoate 100 are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 14, 1986 Original approval · Type 2 - New Active Ingredient
2 products under this application
  • HALDOL · HALOPERIDOL DECANOATE EQ 50MG BASE/ML · INJECTABLE, INJECTION · Discontinued · TE AO
  • HALDOL · HALOPERIDOL DECANOATE EQ 100MG BASE/ML · INJECTABLE, INJECTION · Discontinued · TE AO

Clinical trials

Interventional ClinicalTrials.gov studies with "Haloperidol Decanoate" as an intervention, any sponsor and status, largest first.

All 170 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • weight increased241
  • drug ineffective168
  • extrapyramidal disorder147
  • off label use134
  • akathisia127
  • drug interaction116
  • suicide attempt107
  • leukopenia97
  • toxicity to various agents97
  • neuroleptic malignant syndrome96
  • product use in unapproved indication84
  • treatment noncompliance73

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200430
200534
200642
2007190
200819
200965
201031
201126
201241
201350
201459
201576
201649
201764
201845
201987
202077
2021101
2022134
2023165
2024131
2025146
202681

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Haldol* (Haloperidol Lactate*) · HCPCS J1630

2024 spending

$550

Beneficiaries

98

175 claims

Per beneficiary

$6

2024 ASP limit $1.22 per unit

View as table
YearSpending
2020$498
2021$536
2022$548
2023$625
2024$550

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 69 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.